1 October 2026
Sidley Represents Jiangsu Nhwa Pharmaceutical in Its US$517.5 Million Licensing Transaction With Somnivera
Advising firms
Deal team
7 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Lila Hope Lead | Sidley | Not stated | Technology and Life Sciences Transactions | Not stated |
| Steve Przesmicki Lead | Sidley | Not stated | Emerging Companies and Venture Capital | Not stated |
| Jean Qiu | Sidley | Not stated | Technology and Life Sciences Transactions | Not stated |
| James Mendenhall | Sidley | Not stated | Global Arbitration, Trade and Advocacy | Not stated |
| Chen Yang | Sidley | Not stated | Food, Drug and Medical Device | Not stated |
| Ash Nagdev | Sidley | Not stated | Privacy and Cybersecurity | Not stated |
| Ben Cross | Sidley | Not stated | Privacy and Cybersecurity | Not stated |
4 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 518m (US$517.5 Million)
- What the figure measures
- Total transaction value
- Client
- Jiangsu Nhwa Pharmaceutical Co.Sell-side
- Counterparties
- Somnivera (Buy-side)